Comparative Pharmacology
Head-to-head clinical analysis: CLENPIQ versus HEPTALAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLENPIQ versus HEPTALAC.
CLENPIQ vs HEPTALAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Picosulfate is hydrolyzed by colonic bacteria to the active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM), which stimulates colonic peristalsis and promotes fluid and electrolyte accumulation in the colon. Magnesium oxide and citric acid generate magnesium citrate, an osmotic agent that draws water into the colon. Combined effects induce bowel cleansing.
Ammonia scavenger; lactulose is metabolized by colonic bacteria to organic acids, acidifying the colon, which converts NH3 to NH4+ and promotes ammonia excretion. Lactulose also reduces colonic transit time and bacterial production of ammonia.
Two separate doses: first dose (5 mg prucalopride + 10 mg bisacodyl) orally, followed by a second dose (5 mg prucalopride + 10 mg bisacodyl) orally 6-12 hours later. Total dose: 10 mg prucalopride + 20 mg bisacodyl.
Oral: 3.33 g (30 mL) 3 times daily. Rectal: 200 mL of 30% solution as retention enema, 3 times daily. Intravenous: 30 g as a single dose via intra-abdominal instillation.
None Documented
None Documented
Sodium picosulfate: terminal half-life 7.4 hours (clinically not relevant as action is colonic); magnesium oxide and citric acid produce bicarbonate; half-life not applicable for osmotic component
Terminal elimination half-life is 6-12 hours in patients with normal hepatic function; prolonged in hepatic encephalopathy due to altered clearance (up to 24 hours).
Primarily fecal (97–98%) as unchanged drug; negligible renal excretion (<2%)
Primarily renal (approximately 70-80%) as unchanged drug; minor biliary/fecal elimination (20-30%).
Category C
Category C
Laxative
Laxative